CRVO Key Statistics, Chart & Performance
The current stock price of CRVO is 8.88 USD. In the past month the price increased by 25.6%. In the past year, price decreased by -7.5%.
CRVO Latest News, Press Relases and Analysis
CRVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About CRVO
Company Profile
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Company Info
CERVOMED INC
20 Park Plaza, Suite 424
Boston MASSACHUSETTS US
Employees: 15
Phone: 16177444400
CERVOMED INC / CRVO FAQ
What does CRVO do?
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
What is the stock price of CERVOMED INC today?
The current stock price of CRVO is 8.88 USD. The price decreased by -1.44% in the last trading session.
Does CRVO stock pay dividends?
CRVO does not pay a dividend.
What is the ChartMill rating of CERVOMED INC stock?
CRVO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CERVOMED INC (CRVO)?
CERVOMED INC (CRVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.9).
Should I buy CRVO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRVO.
What is the market capitalization of CRVO stock?
CERVOMED INC (CRVO) has a market capitalization of 82.14M USD. This makes CRVO a Micro Cap stock.
CRVO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CRVO. When comparing the yearly performance of all stocks, CRVO is a bad performer in the overall market: 64.72% of all stocks are doing better.
CRVO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRVO. CRVO has a great financial health rating, but its profitability evaluates not so good.
CRVO Financial Highlights
Over the last trailing twelve months CRVO reported a non-GAAP Earnings per Share(EPS) of -2.9. The EPS decreased by -80.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.58% | ||
| ROE | -98.36% | ||
| Debt/Equity | 0 |
CRVO Forecast & Estimates
13 analysts have analysed CRVO and the average price target is 22.88 USD. This implies a price increase of 157.63% is expected in the next year compared to the current price of 8.88.
For the next year, analysts expect an EPS growth of -21.34% and a revenue growth -32.98% for CRVO